Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PAX-1 by Komipharm International for Metastatic Melanoma: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...
PAX-1 by Komipharm International for Metastatic Prostate Cancer: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Metastatic Prostate Cancer. According to GlobalData,...
PAX-1 by Komipharm International for Gastric Cancer: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Gastric Cancer. According to GlobalData, Phase...
PAX-1 by Komipharm International for Head And Neck Cancer: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Head And Neck Cancer. According to...
PAX-1 by Komipharm International for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...
PAX-1 by Komipharm International for Endometrial Cancer: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
PAX-1 by Komipharm International for Cervical Cancer: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...
PAX-1 by Komipharm International for Metastatic Ovarian Cancer: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData,...
PAX-1 by Komipharm International for Soft Tissue Sarcoma: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
PAX-1 by Komipharm International for Non-Small Cell Lung Carcinoma: Likelihood of Approval
PAX-1 is under clinical development by Komipharm International and currently in Phase II for Non-Small Cell Lung Carcinoma. According to...